Home>>Signaling Pathways>> Neuroscience>> iGluR>>Aniracetam
Aniracetam Catalog No.GC17695

Nootropic drug for senile dementia

Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 72432-10-1 SDF
Chemical Name 1-(4-methoxybenzoyl)pyrrolidin-2-one
Canonical SMILES COC1=CC=C(C=C1)C(=O)N2CCCC2=O
Formula C12H13NO3 M.Wt 219.24
Solubility ≥ 10.96mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



Aniracetam is a nootropic drug in senile dementia [1].

Aniracetam (Ro 13-5057) has a piracetam-like chemical structure, 1-p-anisoyl-2-pyrrolidinone. It is selected from a series of related compounds because of its effect in impaired cognitive functions in rodents. In rats, the administration of aniracetam (30mg/kg orally) markedly prevents the CO2 induced impairment of acquisition. It also significantly increases the percentage of rats showing retention of the learned task in both the scopolamine induced transient retrograde amnesia model (50mg/kg orally) and the electroconvulsive shock induced memory disruption model (50mg/kg orally). Besides that, aniracetam can prevent the disruptive effect caused by chloramphenicol or cycloheximide (30mg/kg orally) [1, 2].

[1] MIZUKI Y, YAMADA M, KATO I, et al. Effects of aniracetam, a nootropic drug, in senile dementia. A preliminary report.: A Preliminary Report. The Kurume medical journal, 1984, 31(2): 135-143.
[2] Cumin R, Bandle E F, Gamzu E, et al. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology, 1982, 78(2): 104-111.